BIOTRONIK Achieves World’s First CRT-D Implant Developed for LBBAP Procedure New Acticor/Rivacor Sky Family Aims to Set a New Benchmark in Physiological Pacing
BIOTRONIK today announced the successful first-in-human implantation of a device from its new Acticor/Rivacor Sky ICD/CRT-D devices, specifically engineered to support conduction system pacing via left bundle branch area pacing (LBBAP). This emerging technique provides a more physiological activation of cardiac tissue for patients requiring ventricular pacing.
The first system has been implanted at the Gold Coast University Hospital in Queensland, Australia by Cardiac Electrophyisologist Dr. Robert Park. This implantation took place as part of the First-in-Human (FIH) study, involving approximately 50 patients across 10 centers. The study aims to preliminarily assess the safety and performance of the new devices and to support future clinical trials.
“It has been our privilege at Gold Coast University Hospital and the Queensland Health Electrophysiology Research Alliance to partner with BIOTRONIK in the trial,” said Dr. Robert Park. “We’re seeing clear benefits for our patients with the enhanced programmability and advanced technology of the new suite of devices. These are complemented by an excellent range of solutions that supports successful conduction system pacing.”
BIOTRONIK’s next-generation Acticor/Rivacor Sky integrates advanced features to deliver precise, patient-specific therapy. The portfolio includes the world’s first CRT-D device for LBBAP. This enables more natural and synchronized heart contractions using the heart’s intrinsic conduction system. Patients with conditions such as atrioventricular (AV) block or left bundle branch block may particularly benefit from this innovative approach.
The new Acticor/Rivacor Sky family will be released worldwide upon successful study completion and regulatory approval.
“We are proud to pioneer advancements in LBBAP,” said Dr. Andreas Hecker, President CRM/EP at BIOTRONIK. “Our enhanced portfolio exemplifies BIOTRONIK’s continued commitment to innovation and excellence in cardiac rhythm management. Setting new standards in cardiac care, we empower physicians to achieve better outcomes and elevate patients’ quality of life.”
-END-
About BIOTRONIK
For over 60 years, BIOTRONIK has stood at the forefront of medical technology, pioneering breakthrough innovations that are transforming the lives of millions affected by heart disease and chronic pain. Rooted in a deep purpose to seamlessly harmonize technology with the human body, we engineer trusted, life-changing therapies through our advanced active implants in Cardiac Rhythm Management, Monitoring, and Neuromodulation, while providing cutting-edge solutions in Electrophysiology. From creating Germany’s first pacemaker in 1963 to breaking new ground in digital technologies and Conduction System Pacing today, BIOTRONIK is continuously raising the bar for quality, performance, and innovation. Headquartered in Berlin, our global reach spans over 100 countries across the Americas, EMEA, and Asia—bringing bold, future-ready solutions that are shaping the next generation of medical technology.
Media Contact
BIOTRONIK Press Office: press@biotronik.com
More Press Releases
-
Image
BERLIN, GermanyPress ReleaseBIOTRONIK Launches Solia CSP S, Aiming to Simplify Conduction System Pacing Procedures
BIOTRONIK, a global leader in medical technology, today announced the market release of Solia CSP S, the latest innovation in its growing portfolio of Conduction System Pacing (CSP) solutions. Solia CSP S is the first and only pacing lead worldwide that combines a fixed screw design with a stylet-driven implantation approach 1, offering physicians a new solution designed to simplify CSP procedures while enhancing control and precision. The first global commercial implants were successfully performed by Dr. Óscar Cano at the University and Polytechnic La Fe Hospital of Valencia, Spain. “In my
-
Image
BERLIN, GermanyPress ReleaseDigital Heart Summit 2024: Pioneering the Future of Cardiology Through Digital Innovation
The Digital Heart Summit 2024, held in Berlin on October 25-26th, concluded with resounding success, bringing together leading minds in eHealth to explore the cutting-edge innovations in digital cardiology. The summit attracted over 100 cardiologists, researchers, and tech innovators from across Europe, making it an excellent platform for interactive exchange and diverse insights in this fast-evolving field. Throughout the two-day event, attendees engaged in discussions on the latest advancements in artificial intelligence, telemedicine, and wearable health devices. These technologies are
-
Image
MONTREAL, CanadaPress ReleaseAmvia Sky Launched in Canada, the World’s First Pacemaker Approved for LBBAP*
Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P generation earlier this year at the Centre Hospitalier de l'Université de Montréal. The patient received an Amvia Sky HF-T QP triple chamber pacemaker device. The first implant follows the full market release of BIOTRONIK’s newest family of pacemaker and CRT-P devices, featuring patient-centric technologies for better patient care and simplified workflows. “The Amvia Sky HF-T QP offers a significant number of advanced features, making it the most complete CRT-P on the market including streamlined
-
Image
BERLIN, GermanyPress ReleaseB3 Clinical Study Results Reveal that Closed Loop Stimulation (CLS) Rate-Adaptive Pacing Delays Subclinical AF in Sinus Node Disease (SND) patients
During a Late-Breaking Session at the annual meeting of the European Heart Rhythm Association (EHRA), Dr. Ennio C. L. Pisanò, Vito Fazzi Hospital, Lecce, Italy, unveiled groundbreaking clinical findings from the randomized, multicenter B3 study 1 regarding the impact of CLS on the incidence of Subclinical AF in SND patients. CLS is a unique rate-adaptive algorithm that is able to detect not only movement but emotional stress, physical stress, or physical activity. In essence, CLS is an impedance-based sensor that translates changes in cardiac contractility to increase heart rate –mimicking a
-
Image
BERLIN, GermanyPress ReleaseBIOTRONIK Introduces New BIOMONITOR IV Insertable Cardiac Monitor with Artificial Intelligence at EHRA Congress 2024
BIOTRONIK announced the CE approval and first European implant of its latest insertable cardiac monitor (ICM). The BIOMONITOR IV features artificial intelligence (AI) for false positive reduction. It is the only ICM on the market with premature ventricular and atrial contraction (PVC and PAC) discrimination capabilities, 1,2 as well as industry-leading signal quality and transmission success for highly reliable remote patient management. 3 False positive detections may take clinicians a considerable amount of time to review. That’s why BIOMONITOR IV features SmartECG, an intelligent system
-
Image
BERLIN, GermanyPress ReleaseBIOTRONIK Introduces World’s First and Only System CE Approved for Left Bundle Branch Area Pacing (LBBAP)
Following the recent CE approval of the Solia S lead 1 for LBBAP, BIOTRONIK proudly announces the world’s first and only complete CSP system, now fully CE-approved for Left Bundle Branch Area Pacing (LBBAP). 2 The BIOTRONIK CSP system comprises three proven components: Selectra 3D catheters offering exceptional handling 3, Solia S leads – the most popular choice of stylet-driven leads for LBBAP 4 providing enhanced stability 3, and the Amvia pacemaker family, the first and only family approved for LBBAP. 2 Notably, this groundbreaking system is the world’s first and only approved MR
-
Image
BERLIN, GermanyPress ReleaseNew BIOlMASTER.Selectra 3D Study Highlights Exceptional Safety and Performance of BIOTRONIK’s Selectra 3D Guiding Catheter for CSP
In a recent prospective, international, multicenter, nonrandomized trial, the BIO|MASTER.Selectra 3D study assessed the performance and safety of BIOTRONIK’s Selectra 3D guiding catheter, revealing compelling insights into its ease of handling and effectiveness. Conducted across 10 centers in Australia, Hong Kong and Europe, the study included 157 patients who underwent a CSP procedure for bradycardia pacing or heart failure indications. The results of this research have been published in the Heart Rhythm O 2 journal. 1 Key Findings of the BIO|MASTER.Selectra 3D Study: High Success Rate in
-
Image
BERLIN, GermanyPress ReleaseBIOTRONIK’s DX Technology Reaches Significant Milestone: 100,000 DX Devices Implanted
BIOTRONIK announced the milestone achievement of 100,000 implanted single-chamber implantable cardioverter-defibrillators (ICDs) equipped with DX Technology. Since the introduction of this unique technology in 2009, clinicians in more than 80 countries across all continents use DX ICDs. “Reaching this significant milestone, BIOTRONIK stands as a proud pioneer and partner in cardiac rhythm management. Our commitment to quality and focus on innovation sets us apart, allowing us to introduce meaningful innovations in the market, such as DX Technology, that make a real difference in patients’
-
Image
BERLIN, GermanyPress ReleaseFirst Implant of Amvia Sky in Europe, the World’s First Pacemaker Approved for LBBAP*
The first implant in Europe of BIOTRONIK’s latest pacemaker and CRT-P generation was conducted in early August by Prof. Dr. Jan De Pooter at the University Hospital Ghent in Belgium. The patient who received an Amvia Sky dual chamber pacemaker device was a 68-year-old man suffering from paroxysmal AV-block strongly limiting his physical efforts. “The implantation went on straightforward and very smoothly,” commented Prof. De Pooter after the procedure. “LBBAP enables pacing in a very natural, physiological way, benefiting the patient by offering physiological pacing and minimizing the risk for
-
Image
BERLIN, GermanyPress ReleaseREACT DX Registry Highlights Relevance of Atrial High-Rate Episode Remote Monitoring in ICD Patients
A recent study highlights that implantable cardioverter-defibrillator (ICD) patients with new-onset atrial high-rate episodes (AHRE) often show high stroke risk while not being on oral anticoagulation (OAC), underlining the relevance of continuous AHRE burden monitoring. 1 The study also reports that the combination of BIOTRONIK’s unique DX ICD system with Home Monitoring is an effective and convenient way to detect AHRE. 1 REACT DX is a prospective, multi-center registry that enrolled 234 de novo ICD patients from 14 centers in Germany. It assessed the incidence of new-onset AHRE in an ICD
-
Image
BERLIN, GermanyPress ReleaseBIOTRONIK Receives CE Approval for the World’s First Pacemaker and CRT-P Family Approved for Left Bundle Branch Pacing*
BIOTRONIK, a leading global medical technology company with 60 years of experience in developing trusted cardiovascular and endovascular solutions, announced today the latest addition to its cardiac rhythm management portfolio. "We are excited to have received CE mark for our newest technology – the world’s first pacemakers and CRT-Ps approved for left bundle branch pacing. Amvia Sky and Amvia Edge represent cutting-edge innovation and incorporate the latest cardiology trends," says Dr. Andreas Hecker, President CRM/EP at BIOTRONIK. In 1963, BIOTRONIK introduced the first German implantable
-
Image
BERLIN, GermanyPress ReleaseDX Technology Demonstrates High Detection Accuracy for Atrial Fibrillation in Single-Chamber ICD Patients
Results from the MATRIX study show that the high detection accuracy of DX single-lead ICD systems for atrial fibrillation (AF) episodes (99.7% for ≥ 1h episodes) in combination with the strong transmission performance of BIOTRONIK Home Monitoring ® allows for reliable guideline-recommended remote monitoring of subclinical AF. The findings were published in Europace earlier this week. 1 MATRIX evaluated the utility of the DX-ICD system (atrial signal detection via a floating dipole integrated in the ICD lead) for remotely monitoring atrial high-rate episodes (AHRE) and their duration
-
Image
BERLIN, GermanyPress ReleaseBIOTRONIK Conduction System Pacing Tools Received CE Mark for Left Bundle Branch Area Pacing
BIOTRONIK announced today that it has received CE approval for the Selectra 3D implant tools to include left bundle branch area pacing (LBBAP) in addition to His-bundle pacing (HBP). Commonly referred to as conduction system pacing (CSP) these two approaches have emerged as a physiologic pacing alternative to avoid dyssynchronous contraction of the heart which can induce various negative long-term effects for patients. 1-3 Approved in 2021 for HBP, Selectra 3D’s safety and effectiveness for CSP has been shown in over 10 studies with more than 1,000 patients. In the multi-center Belgium